Oncology

The program develops patient-centered oncology pharmacists through comprehensive training.

Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.

Of these chemicals, 414 were found to be commonly used in plastics and consumer goods, such as food packaging and personal care products.

Pharmacists bring a unique perspective to health care that bridges clinical knowledge, patient-centered care, and operational expertise.

The treatment landscape for multiple myeloma continues to evolve.

A study in Lancet Haematology revealed that minority ethnic patients face significantly poorer outcomes after hematopoietic cell transplantation compared to White patients.

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.

The indication is for patients with locally advanced or metastatic disease who have not previously received treatment with an ALK-inhibitor.

The researchers suggest that an imbalance between pro-inflammatory and resolving lipid mediators may drive tumor growth.

The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

Alison Moskowitz, MD, discusses the clinical considerations, dosing strategies, and the critical role of pharmacists in managing toxicities and tailoring treatment plans for dual-targeted therapy with ruxolitinib and duvelisib.

Improvements were observed regardless of whether patients initiated ruxolitinib in the second or third line of treatment.

Compared with placebo, patients with relapsed/refractory (R/R) follicular lymphoma (FL) who were treated with tafasitamab showed a median progression-free survival (PFS) of 22.4 months.

Currently, the treatment is undergoing evaluation in a phase 2a trial.

This update follows May 2021 guidelines which recommended patients with primary biliary cholangitis (PBC) with advanced cirrhosis discontinue obeticholic acid.

The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.

Patients with chronic graft-versus-host disease (cGVHD) were most likely to receive belumosudil in the fourth line (33.7%) setting or the fifth through seventh line (33.1%).

The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.

Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.

Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.

Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.

PLT012 demonstrates its potential against multiple tumors with unmet medical needs.

Dose rounding within an acceptable range can provide cost savings and minimize waste, but requires careful interprofessional collaboration and patient education.

Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.

This builds off prior data that showed safety and efficacy of CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL).

Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.